Q3 2025 · 13F-HR
Pivotal bioVenture Partners Investment Advisor LLCholdings as filed
Filed 2025-11-13 · accession 0001012975-25-000748
The Brief · Pivotal bioVenture Partners Investment Advisor LLC · Q3 2025
AI · grounded in 13F
Pivotal bioVenture Partners Investment Advisor LLC established a new position in Vaxcyte Inc PCVX valued at $49.4M. The fund also initiated new stakes in Oculis Holding AG OCS for $40.4M and Arcutis Biotherapeutics Inc ARQT for $39.9M. Additional new positions include Zenas Biopharma Inc ZBIO, Trevi Therapeutics Inc TRVI, and Immunome Inc IMNM. The fund ended the period with 10 positions and total AUM of $172.9M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 92243G108 | PCVX | VAXCYTE INC | $49.4M | 28.6% | 1,372,425 | Common | SHARED |
| H5870P102 | OCS | OCULIS HOLDING AG | $40.4M | 23.4% | 2,300,774 | Common | SHARED |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $40.0M | 23.1% | 2,120,508 | Common | SHARED |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $17.3M | 10.00% | 779,045 | Common | SHARED |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $11.5M | 6.65% | 1,256,782 | Common | SHARED |
| 45257U108 | IMNM | IMMUNOME INC | $5.9M | 3.40% | 502,512 | Common | SHARED |
| 09077V100 | BIOA | BIOAGE LABS INC | $3.8M | 2.22% | 653,374 | Common | SHARED |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $2.9M | 1.68% | 595,518 | Common | SHARED |
| 75120L100 | RLYB | RALLYBIO CORP | $1.2M | 0.69% | 2,404,644 | Common | SHARED |
| 097702203 | BOLT | BOLT BIOTHERAPEUTICS INC | $503,128 | 0.29% | 94,573 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.